Pillar5 Pharma

What Pillar5 Pharma does

Pillar5 Pharma is a Canadian contract development and manufacturing organization (CDMO) founded in 2009 and headquartered in Arnprior, Ontario. The company serves pharmaceutical customers with two primary service lines: aseptic sterile ophthalmic solutions manufacturing — including market-leading Multi-Dose Preservative Free (MDPF) filling capabilities — and solid dose tablet production covering OTC, prescription, and animal health products across nervous system, respiratory, and other therapeutic categories. Production capacity stands at 30 million ophthalmic bottles per year and 255 million solid dose tablets per year, supported by 210+ employees including 50 specialists in Quality, Compliance, and technical transfer.

The business operates a B2B contract manufacturing model, generating revenue through manufacturing fees, technical services, and supply agreements with major multinational pharmaceutical clients. The facility has been Health Canada approved and has held an FDA Drug Establishment Registration for manufacturing and analytical testing for 14 years. Additional service offerings include analytical and microbiological testing, sterility assurance, and full validation and qualification support across the product development-to-manufacturing lifecycle. Pricing is not publicly disclosed and follows a quote-based B2B CDMO structure.

In December 2025, Prestige Consumer Healthcare (NYSE: PBH) completed its acquisition of Pillar5 Pharma to secure supply for eye care brands including Clear Eyes and TheraTears and to expand long-term production capacity. Prior to this acquisition, the company was associated with the ANJAC Health and Beauty group, which employed 3,000+ people across its broader industrial platform. Leadership comprises Dwight Gorham as President & CEO and Claude Germain as Chairman of the Board.

Name

Pillar5 Pharma

Legal name

Pillar5 Pharma Inc.

Website

https://pillar5pharma.com/

Company type

Private

Founded year

2009

Operating status

Acquired

Headcount range

101–250 employees

Short description

Pillar5 Pharma is a Canadian CDMO specializing in sterile ophthalmic solutions manufacturing with market-leading Multi-Dose Preservative Free (MDPF) filling technology and solid dose tablet production for major multinational pharmaceutical customers. It is now a subsidiary of Prestige Consumer Healthcare.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (Sterile Ophthalmic CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

• Sterile ophthalmic manufacturing
• Contract pharmaceutical manufacturing
• Multi-dose preservative-free technology
• Solid dose tablet production
• Aseptic filling services

Headquarters

HQ city

Arnprior

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Pillar5 Pharma operates as a CDMO providing contract manufacturing services for sterile ophthalmic solutions and solid dose tablets to pharmaceutical companies. Revenue is generated through manufacturing fees, technical services, and supply agreements with major pharma customers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Pillar5 Pharma is a Canadian contract development and manufacturing organization (CDMO) that provides aseptic processing, filling, and packaging of sterile ophthalmic solutions, with leadership in Multi-Dose Preservative Free (MDPF) technology in North America. The company also manufactures solid dose tablets for OTC and prescription products across nervous system, respiratory, and animal health categories, supported by analytical, microbiological, validation, and qualification services.

Product overview

Pillar5 Pharma is a contract development and manufacturing organization (CDMO) offering two primary service lines: sterile ophthalmic solutions manufacturing with leading Multi-Dose Preservative Free (MDPF) technology, and solid dose tablet production for OTC and prescription pharmaceuticals. The company operates as a full-service provider supporting pharmaceutical customers from product development through manufacturing, with capabilities in aseptic processing, filling, packaging, and validation services.

Differentiator

Problem solved

Functional benefit

Products and services

• Sterile Ophthalmic Solutions Manufacturing

Quantifiable outcome

• 100% of ANJAC innovations featuring at least one sustainable objective by 2026
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Prestige Consumer HealthcarecoreStrategic or Co-development PartnerPrestige Consumer Healthcare acquired Pillar5 Pharma to enhance supply capabilities in the eye care category and expand long-term production capacity. The acquisition adds MDPF manufacturing expertise to Prestige Consumer's existing eye care brands including Clear Eyes and TheraTears. Pillar5 Pharma now operates as a subsidiary under Prestige Consumer Healthcare Inc.

Scale indicators5 records

Recent moves4 records

Expansion highlights5 records

Broad incumbents

• Recipharm: European-headquartered CDMO with sterile liquids, semi-solids, and solid dose manufacturing; competes for the same types of contract sterile ophthalmic and oral dose work as Pillar5.
• PCI Pharma Services: Large global CDMO offering sterile fill-finish, ophthalmic manufacturing, and solid dose services; overlaps with Pillar5 but at broader scale and across multiple therapeutic areas.
• Aenova Group: European CDMO with solid dose, semi-solid, and sterile liquid capabilities including ophthalmic; a comparable incumbent serving multinational pharma with similar dosage forms.
• Catalent: One of the largest global CDMOs with extensive sterile fill-finish and oral solid dose capabilities including ophthalmic programs; a broader incumbent in Pillar5's product categories.
• Bora Pharmaceuticals: Global CDMO offering sterile, ophthalmic, and oral solid dose services following acquisitions of Upsher-Smith and generics manufacturing assets; competes in Pillar5's core dosage forms.
• Curia (formerly AMRI): Integrated CDMO with sterile fill-finish and oral solid dose capabilities serving pharmaceutical clients; comparable as a full-service contract manufacturer across overlapping dosage forms with Pillar5.

Direct peers

• Grand River Aseptic Manufacturing (GRAM): FDA-inspected sterile injectable CDMO with ophthalmic and small-batch aseptic filling capabilities; competes for the same preservative-free and sterile ophthalmic contract manufacturing work as Pillar5.
• Renaissance Lakewood (RLS): Sterile liquid and ophthalmic contract manufacturer offering aseptic filling of ophthalmics and other sterile solutions; overlapping directly with Pillar5's sterile ophthalmic and MDPF business.
• Woodstock Sterile Solutions: U.S.-based sterile contract manufacturer specializing in sterile ophthalmic and injectable liquids; the most directly comparable pure-play ophthalmic sterile CDMO to Pillar5's MDPF and aseptic filling services.
• CoreRx: Sterile and non-sterile CDMO with capabilities in ophthalmic, liquid, and semi-solid manufacturing; comparable in scale and service mix to Pillar5's ophthalmic and solid dose lines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pillar5-pharma

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pillar5 Pharma